Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases.
Closing unlocks the next phase of genomic medicine, offering an end-to-end centralized and decentralized model for offering clinically-actionable genomic insights at a global scale.
Combining GeneDx’s industry-leading rare disease data asset and Fabric Genomics’ AI-powered platform furthers the Company’s leadership and creates an unrivaled platform to deliver global access to genomic information.
Accelerates the NICU, enables newborn screening, and opens global market opportunities with on-site sequencing and decentralized interpretation.
Fabric Genomics, the leader in artificial intelligence (AI)-powered next generation sequencing interpretation, is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.
Fabric AI technology for interpretation of the human genome, powered by the Fabric GEM AI algorithm, will be adapted into the FirstSteps clinical support tool, empowering clinicians to provide timely medical intervention for patients with rare genetic diseases in Greece.
The partners will offer an integrated sample-to-report rapid nanopore sequencing analysis platform for neonatal/paediatric intensive care units to support clinicians in acute settings.
Priced at $1,000 per sample, the new test promises to be competitive with other offerings in the market
while offering better cost transparency.
The newly formed partnership will enable clinical genomics laboratories to move from sample to evidence-backed analysis to actionable clinical reports using a push-button solution.
Hofher, Former Chief Scientific Officer of GeneDx, is the latest addition to Fabric Genomics’ expanding leadership team
A new study in Nature Communications describes and examines the performance of Rady Children’s Institute for Genomic Medicine’s Genome-to-Treatment (GTRx™), a clinical decision support tool on which Fabric is a research collaborator.
